The user experienced significant hair thinning despite using finasteride and minoxidil, leading to concerns about whether it's a temporary shed or a more serious issue. They plan to start using RU58841 and are advised to consult a doctor to rule out other causes like autoimmune disorders.
The user experienced increased hair loss with topical finasteride and is considering switching to oral finasteride. Others shared mixed experiences, with some suggesting oral finasteride is more effective, while others noted individual results vary.
The conversation discusses the use of pyrilutamide for hair loss, specifically its impact on shedding. The user is inquiring if others have experienced increased or decreased shedding after starting pyrilutamide.
Finasteride isn't improving hair loss, possibly due to prior accutane use, which may have caused additional shedding. The user is concerned about ongoing hair loss despite treatment.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
A user reports experiencing insomnia as a side effect of taking finasteride for hair loss, which takes 1 to 2 hours to fall asleep and results in only about 5 hours of sleep per night. They suspect the cause is related to the downregulation of neurosteroids due to finasteride.
Creatine does not significantly affect hair loss when taking finasteride. Some users report no change, while others believe it may accelerate hair loss if predisposed to male pattern baldness.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.
Increased scalp itching during shedding phases while on finasteride treatment may coincide with hair regrowth and recovery. This suggests that itching might not always indicate continued hair loss and could encourage persistence with the treatment.
The user is experiencing severe hair loss despite using finasteride for 10 months and suspects scalp buildup might be contributing. Suggestions include using ketoconazole shampoo, consulting a dermatologist, and trying terbinafine cream.
RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.
The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
Finasteride users discuss potential side effects, including Post Finasteride Syndrome (PFS), with varying opinions on its legitimacy and impact. Some users report side effects like changes in semen consistency and reduced pre-ejaculate, while others emphasize the rarity and reversibility of side effects.
A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
High body fat can increase estrogen levels, leading to side effects when using finasteride. Reducing body fat and checking hormone levels can help manage these side effects.
Finasteride users discuss the potential impact of creatine on hair loss and libido. Some report no change, while others notice increased hair thinning, suggesting mixed experiences.
Clascoterone stopped shedding for one user, but no visual regrowth was noted after 3 months. The user experienced side effects with finasteride, dutasteride, and RU58841, but not with oral minoxidil and clascoterone.
Combining Minoxidil with Finasteride or RU58841 may cause interference, irritation, or reduced absorption. It might be better to apply one topical at a time and wait an hour before applying another.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.
A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.
The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.